Rate My Professor Rimma Goldberg

Rimma Goldberg, MBBS (Hons), BMedSci (University of Melbourne, 2007), FRACP, PhD in Immunology and Mucosal Biology (King’s College London, 2019), is an Associate Professor at the Centre for Inflammatory Diseases, School of Clinical Sciences at Monash Health, Faculty of Medicine, Nursing and Health Sciences, Monash University. She serves as a consultant Gastroenterologist at Monash Health, where she completed her gastroenterology training, having previously trained at St Vincent’s Hospital. Goldberg also undertook an Inflammatory Bowel Disease Fellowship at Guy’s and St Thomas’ NHS Trust. In addition to her clinical and research roles, she coordinates the BMedSc(Hons) program in the School of Clinical Sciences and participates as an investigator in industry-led Phase 2/3 clinical trials for inflammatory bowel disease (IBD), ensuring patients access advanced therapies. Her clinical practice encompasses managing complex IBD, functional gut disorders, irritable bowel syndrome, liver disease, and bowel cancer surveillance, including gastroscopy and colonoscopy procedures.

Goldberg’s research focuses on developing novel cell-based therapies for IBD, particularly regulatory T cell (Treg) therapies to suppress inflammation in Crohn’s disease. During her PhD, she pioneered a Treg-based treatment now in Phase 1 clinical trials in the United Kingdom. Since returning to Australia, she has built collaborative networks to translate this therapy locally, supported by the School of Clinical Sciences Career Development Fellowship and a Crohn’s and Colitis Australia Research Prize. She leads grants including antigen-specific Treg therapy for ulcerative colitis, gastrointestinal-restricted ALK5 inhibitors for intestinal fibrosis, and studies on thiopurine metabolites and pharmacotherapies in pregnancy-related IBD. Her publications feature in high-impact journals such as Gut, Gastroenterology, and Nature Reviews Gastroenterology. Key papers include “Vedolizumab and Ustekinumab Levels in Pregnant Women With Inflammatory Bowel Disease and Infants Exposed In Utero” (Clinical Gastroenterology and Hepatology, 2025), “Thiopurine Metabolite Shunting in Late Pregnancy Increases the Risk of Intrahepatic Cholestasis of Pregnancy in Women with Inflammatory Bowel Disease” (Journal of Crohn’s and Colitis, 2024), “Colonic cytomegalovirus DNA detection by polymerase chain reaction does not influence outcomes in inflammatory bowel disease” (Internal Medicine Journal, 2024), “Thrombocytosis and Transaminitis in Infants Born to Women With Inflammatory Bowel Disease” (Inflammatory Bowel Diseases, 2024), and “Thiopurine metabolite testing in inflammatory bowel disease” (Therapeutic Advances in Gastroenterology, 2016). Awards include the British Society of Gastroenterology Best Scientific Abstract Award and the Society of Mucosal Immunology Rising Stars in Mucosal Immunology award.